top of page
  • Synergy between LAG3 and other inhibitory receptors particularly PD1

  • Immune modulation of T cell subsets by LAG3 and PD1

  • Identification of novel inhibitory mechanisms

Selected publications:

Huan C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Lavitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DAA (2004). Role of LAG-3 in regulatory T cells. Immunity 21: 503-13 [Pubmed]

Woo S-R*, Turnis ME*, Goldberg MV*, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Vogel P, Liu C-L, Tangsombatvisit S, Grosso, JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DAA (2012). Immune inhibitory molecular LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Research 72: 917-927 [Pubmed]

Zhang Q, Vignali DAA (2016). Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity 44: 1034-1051 [Pubmed]

Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, Normolle D, Bettini M, Workman CJ, Vignali DAA (2017). LAG-3 limits regulatory T cell proliferation and function in autoimmune diabetes. Science Immunology 2: eaah4569

bottom of page